KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $27.9 million.

  • Rigel Pharmaceuticals' Consolidated Net Income rose 12461.96% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 281795.93%. This contributed to the annual value of $17.5 million for FY2024, which is 16961.06% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Consolidated Net Income stood at $27.9 million, which was up 12461.96% from $59.6 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Consolidated Net Income high stood at $59.6 million for Q2 2025, and its period low was -$27.4 million during Q1 2022.
  • Moreover, its 5-year median value for Consolidated Net Income was -$5.7 million (2023), whereas its average is $781473.7.
  • In the last 5 years, Rigel Pharmaceuticals' Consolidated Net Income tumbled by 16953.21% in 2022 and then skyrocketed by 588766.99% in 2025.
  • Rigel Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$22.6 million in 2021, then soared by 106.2% to $1.4 million in 2022, then plummeted by 47.39% to $737000.0 in 2023, then soared by 1843.28% to $14.3 million in 2024, then surged by 94.81% to $27.9 million in 2025.
  • Its Consolidated Net Income was $27.9 million in Q3 2025, compared to $59.6 million in Q2 2025 and $11.4 million in Q1 2025.